vimarsana.com

Latest Breaking News On - First in class inhibitor - Page 1 : vimarsana.com

Tachyon Presents Preclinical Data on the Company s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

HOUSTON (BUSINESS WIRE) Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.